Press "Enter" to skip to content

FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) as First-Line Maintenance with Bevacizumab in Advanced Ovarian Cancer and Grants Priority Review – Business Wire

admin 0

FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) as First-Line Maintenance with Bevacizumab in Advanced Ovarian Cancer and Grants Priority Review  Business Wire
“ovarian cancer” – Google News

(Visited 5 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *